Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Loncastuximab tesirine consolidation after short-course R-BAC in BTKi-treated or BTKi-intolerant relapsed/refractory mantle cell lymphoma
2021-000715-23Phase 2Active
- Sponsor
- Fondazione Italiana Linfomi
- Start
- Oct 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of loncastuximab tesirine in mantle cell lymphoma (MCL), sponsored by Fondazione Italiana Linfomi. Primary endpoint: 12-month progression-free survival. Started Oct 2021; status: active.
02
Drugs
loncastuximab tesirine
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on 2021-000715-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000715-23.